Cookie Settings

Mars Petcare receives EC approval to complete acquisition of AniCura

Press release

Yesterday, Mars Petcare received approval from the European Commission to complete the acquisition of AniCura. As part of the acquisition, AniCura’s procurement platform for independent veterinary clinics, VetFamily, will be divested.

In June 2018, Mars Petcare announced that it had reached an agreement to acquire AniCura from its majority owner Nordic Capital Fund VIII and other shareholders, subject to approvals from regulatory authorities. Yesterday, the acquisition was approved by the European Commission, subject to the divestiture of AniCura’s procurement platform VetFamily, meaning that AniCura will join Mars Petcare’s family of veterinary care businesses alongside US-based Blue Pearl, VCA Hospitals, Pet Partners and Banfield as well as UK-based Linnaeus.

–  We are excited to join Mars Petcare and continue to shape the future of European veterinary care together with some of the world’s leading veterinary care companies. As part of a long-term and family-owned group we are well equipped to continue our journey with a clear focus on quality and patient safety, people and entrepreneurship, says Peter Dahlberg, CEO AniCura.

As a consequence of the acquisition by Mars Petcare, AniCura’s subsidiary VetFamily, a separate operation within the group, will be divested. VetFamily is a procurement platform bringing together independent clinics to enjoy benefits within areas such as purchasing, administration and education. VetFamily has grown rapidly over the past years and today has more than 1,000 member clinics across five countries.

–  VetFamily is a great business that provides community and advantages for independent clinics otherwise only available for larger organisations. The business is growing rapidly, enjoys many development opportunities and is sizeable enough to become an independent company. Interest for VetFamily is significant and we are committed to find the right future home for VetFamily’s members and employees, says Peter Dahlberg.

AniCura’s existing management team, led by CEO Peter Dahlberg, will continue to lead and develop AniCura, with a maintained focus on quality care, innovation and entrepreneurship, nurturing a strong culture and taking clinical decisions close to patients and customers.

 

For further information please contact

Maria Tullberg, Group Communications Manager, AniCura, +46 736 268 886